Details of the Drug

General Information of Drug (ID: DMXI8X0)

Drug Name
Mitapivat
Synonyms AG-348
Indication
Disease Entry ICD 11 Status REF
Hereditary haemolytic anemia 3A10.3 Approved [1]
Pyruvate kinase deficiency 5C53.00 Phase 2 [2]
ATC Code
B06AX04: Mitapivat
B06AX: Other hematological agents
B06A: OTHER HEMATOLOGICAL AGENTS
B06: OTHER HEMATOLOGICAL AGENTS
B: BLOOD AND BLOOD FORMING ORGANS
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C24H26N4O3S
Canonical SMILES
C1CC1CN2CCN(CC2)C(=O)C3=CC=C(C=C3)NS(=O)(=O)C4=CC=CC5=C4N=CC=C5
InChI
1S/C24H26N4O3S/c29-24(28-15-13-27(14-16-28)17-18-6-7-18)20-8-10-21(11-9-20)26-32(30,31)22-5-1-3-19-4-2-12-25-23(19)22/h1-5,8-12,18,26H,6-7,13-17H2
InChIKey
XAYGBKHKBBXDAK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
59634741
CAS Number
1260075-17-9
UNII
2WTV10SIKH
DrugBank ID
DB16236
TTD ID
D0C8AP
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Pyruvate kinase PKLR (PKLR) TT31N4S KPYR_HUMAN Activator [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 216196.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)